by Nathaniel Harding | Feb 22, 2024 | Blog
A Cortado Conversation with CorriXR Therapeutics CEO Deborah Moorad Read the full story here Cortado is thrilled to invest in CorriXR Therapeutics, an early-stage biotech company commercializing a platform gene editing technology with a first-use case in oncology. The...
by Nathaniel Harding | Feb 1, 2024 | Blog
2023 Lookback for Cortado Ventures — Read the full story here At Cortado Ventures, we’re excited for 2024. In our company meeting this week, we strategized our position in the Midcontinent market and what it will take to source, select, and support the best and...
by Cortado Ventures Media | Jan 29, 2024 | Blog, Media, Portfolio Companies
Why We Invested: Lumata Health Pioneering Next-Generation Eye Care Authored by Cody Merrill At Cortado Ventures, we are in the venture capital business of maximizing risk-adjusted returns with high-potential, early-stage startups. We seek...
by Nathaniel Harding | Jan 4, 2024 | Blog
Preclinical biotechnology company initially focusing on therapeutic drug development to promote remyelination in Multiple Sclerosis OKLAHOMA CITY, Dec. 14, 2023 /PRNewswire/ — Cadenza Bio, Inc. (Cadenza), a privately-held biotechnology company focused on...
by Cortado Ventures Media | Nov 15, 2023 | Blog, Media, Portfolio Companies
Read the full story here Authored by Susan Moring, Cortado Ventures General Partner One of our favorite types of startups to invest in at Cortado are those who are building underlying technologies that enable businesses and industries to operate more...
by Nathaniel Harding | Nov 2, 2023 | Blog
At Cortado Ventures, we back entrepreneurs that are inventing the future, and we are thrilled about our investment in Moat Biotechnology. Moat’s technology is based on a next-generation adenovirus platform from the Mayo Clinic. Our General Partner Mike Moradi...
